



© SwissTech Convention Center

**Abstract-Deadline**  
**05.05.2019**

# 4th SFCNS Congress

Preliminary Program

## Swiss Federation of Clinical Neuro-Societies

**October 23 - 25, 2019**

SwissTech Convention Center, EPFL  
Lausanne

[sfcns2019.congress-imk.ch](http://sfcns2019.congress-imk.ch)

# WELCOME

## 4th SFCNS Congress

It is our great pleasure to announce the 4th congress of the Swiss Federation of Clinical Neuro-Societies (SFCNS), which will take place in Lausanne at the SwissTech Convention Center from October 23 to 25, 2019.

Starting with the the 6 original (founding) societies (Neurology, Neurosurgery, Neuroradiology, Neuropediatrics, Neuropathology and Clinical Neurophysiology), the federation has over the last years grown to encompass most if not all societies and individuals involved in managing diseases of the central nervous system in Switzerland.

Ever since its foundation, the SFCNS has undertaken efforts to improve the quality and visibility of Swiss neuroscience – locally, nationally and internationally. This has been done with great success by promoting clinical excellence, scientific research as well as political lobbying. Further, collaboration and exchange between the various clinical neurosocieties which form the SFCNS have been promoted.

The SFCNS has thus successfully been active in the creation and certification of world-class stroke centers as well as in defining the criteria by which Highly Specialized Medicine (HSM) is to be practiced in Switzerland in the domain of clinical neurosciences. Since its founding in 2009 and the first congress in 2010, the SFCNS has continuously grown and expanded its success, vision and influence. In addition to the congress, the Society has successfully developed summer schools to attract its members and further established the Journal Clinical and Translational Neuroscience as its own vehicle for scientific publications.

One of the central factors for the success of the SFCNS is its triennial congress, which represents a unique encounter between not just the various societies which form its core but also of adjacent specialities that will contribute to our common future. Thus, it is exceedingly important that the congress does not only represent the various member societies, but that it also has a spirit of its own.

The fourth congress of the SFCNS is this time not just held in any congress center, but in the heart of Swiss technological innovation at the SwissTech Convention Center, which is located in the heart of the campus of the Ecole Polytechnique Fedeale de Lausanne (EPFL). This represents a breakout from the previous locations Basel and Montreux and is of extreme importance to us all, since clinical neuroscience has benefited from advances in technology since its inception. Further, leaders in neuroscience very often contribute to technological developments themselves. Therefore, additionally to the traditional neuro-science participants we will see participants from fields of technologies such as basic neuroimaging, robotics and artificial intelligence that have contributed and will further contribute to the definition of the way clinical neuroscientists work over the next century.

The congress program is extremely rich and varied and proposes a multitude of formats for presenting knowledge and advances in neuroscientific areas: the days will start with plenary sessions that will be followed by satellite symposia and parallel sessions devoted to topics of clinical and scientific interest.

We hope that you will join us in Lausanne for this exciting event and that you will have as much pleasure attending the congress as we have in organizing it.



Prof. Karl Olof Lövblad, MD  
Congress President



Prof. Karl Schaller, MD  
President SFCNS

# PROGRAM

Wednesday, 23.10.2019 | 09:45-18:45

## Plenary Session

### Keynote Lecture

Chair: K. Rösler, Bern und Basel, CH

**Presence hallucinations: from epilepsy and Parkinson's disease to neuroscience robotics**

O. Blanke, Geneva, CH

## Plenary Session

### Smarter Devices

Chair: K. Rösler, Bern und Basel, CH

**Sensing and computing bits in Edge AI: enabling technologies for future Human Avatars**

A. Ionescu, Lausanne, CH

**Virtual reality approaches to study and improve cognitive and motor deficits after stroke**

A. Serino, Lausanne, CH

**Mobile technologies for remote, patient driven neuro-monitoring and stimulation**

W. Karlen, Zurich, CH

### Satellite Symposium

Novartis Pharma Schweiz AG  
**When progression takes over: novel treatment options for SPMS**

### Satellite Symposium

Mitsubishi Tanabe  
Pharma GmbH

### Satellite Symposium

### Parallel Session

**Acute-Stroke**

### Parallel Session

**Neuro-Intensive Care**

### Parallel Session

**YouClin**

### Parallel Session

**Models of human memory – Part I**

### Parallel Session

**Neurosurgery/  
Neuroradiology**

### Parallel Session

**Baasch-Medicus-Lecture**

### Parallel Session

**Intraoperativ  
Neuromonitoring**

### Parallel Session

**YouClin**

### Parallel Session

**Models of human memory – Part II**

### General Assembly

**Neurological Society  
(SNS)**

# PROGRAM

Thursday, 24.10.2019 | 08:15-18:45

## Plenary Session

### Neuroimmunology and Neuroinflammation Crosstalks

Chairs: K. Do Cuénod, Lausanne; K. Nedeltchev, Aarau, CH

#### Pediatric inflammatory brain diseases – overview and management

S. Bigi, Bern, CH

#### The T cell/phagocyte interface in neuroinflammation

B. Becher, Zurich, CH

#### Neuroinflammation and oxidative stress in schizophrenia pathophysiology: a translational approach

K. Do Cuénod, Lausanne, CH

## Plenary Session

### Low back pain - a global challenge

Chairs: B. Tettenborn, St. Gallen; J. Fandino, Aarau, CH

#### The burden of low back pain

J. Petersen, Zurich, CH

#### Added value of imaging in acute low back pain

J. Van Goethem, Antwerpen, BE

#### Sense and nonsense in lumbar spinal stenosis surgery

A. Raabe, Bern, CH

#### Convincing reasons for the conservative approach

Susanne Hartmann-Fussenegger, St.Gallen

ePoster	ePoster	ePoster	ePoster	SFND Symposium
Satellite Symposium	Satellite Symposium	Satellite Symposium		
Roche Pharma (Schweiz) AG Latest clinical developments in Neuroscience	Alexion Pharma GmbH The role of complement in generalized myasthenia gravis			
Parallel Session	Parallel Session	Parallel Session	Parallel Session	SFND Symposium
Neuromuscular	Intraoperative Imaging	YouClin	Urbanicity and Psychosis	
Parallel Session	Parallel Session	Parallel Session	Parallel Session	General Assembly
Ultra high-field brain imaging	Spine Surgery	Swiss Narcolepsy Network (SNaNe)	Primary Progressive Aphasia	Headache Society (SHS)
General Assembly	General Assembly	General Assembly	General Assembly	General Assembly
Clinical Neurophysiology (SSNC)	Neurosurgery (SSNS)	Neuroradiology (SSNR)	Biological Psychiatry (SSBP)	Behavioural Neurology (SSBN)

# PROGRAM

Friday, 25.10.2019 | 08:30-16:00

## Plenary Session

### Dangerous Headache

Chairs: A. Raabe, Bern; Ch. Stippich, Zurich; CH

#### Dangerous headaches: not always hemorrhages

A. Straube, Munich, DE

#### Specific Imaging Strategies and Findings in Patients with Headaches

O. Jansen, Kiel, DE

#### Special aspects: CSF and vascular causes

J. Beck, Freiburg, DE

Parallel Session	Parallel Session	Parallel Session	IG-NOPPS	Symposium
Imaging findings in patients with headache	Vertigo	YouClin	IG-NOPPS	OHBM Alpine Chapter
Satellite Symposium	Satellite Symposium	Satellite Symposium		Symposium
Merck (Schweiz) AG The changing treatment landscape of multiple sclerosis	Eli Lilly Suisse (SA)			OHBM Alpine Chapter
Parallel Session	Parallel Session	Parallel Session	IG-NOPPS	Symposium
Headache for Practitioners - case based	Behavior Neurology	EEG/Epilepsy	IG-NOPPS	OHBM Alpine Chapter

## Plenary Session

### Brain of the future

Chair: K. Lövblad, Geneva; Andrea Rossetti, Lausanne, CH

#### Neurology: "Eppur si muove"

#### From a diagnostic to a therapeutic specialty

C. Bassetti, Bern, CH

#### The prevention of stroke and Alzheimer's disease: the old and the new

G. Frisoni, Geneva, CH

#### Advances and Perspectives on the treatment of neurovascular diseases

V. M. Pereira, Toronto, USA

#### Neuroprosthetic technologies for restoring leg motor control after paralysis

J. Bloch, Lausanne, CH

# REBIF®: SEIT ÜBER 20 JAHREN AN IHRER SEITE<sup>1</sup>

## Rebif®/Rebif® multidose™/Rebif® RebiDose™ Interferonon beta-1a ADNr

**I:** Patienten mit einem ersten klinischen, auf Multiple Sklerose (MS) hinweisenden neurologischen Ereignis bei Ausschluss anderer Diagnosen und glz. hohem Risiko für das Auftreten einer schubförmigen MS. Schubförmige MS. D: 1. Allg. 4,4 µg, dreimal pro Woche subkutan. **Kt:** Behandlungsbeginn während der Schwangerschaft. Überempfindlichkeit gegen einen Inhaltsstoff, schwerwiegende Depressionen und/oder Suizidgedanken. **V:** Thrombotische Mikroangiopathie, Depressive Störungen, Krampfleiden, nicht adäquat therapierte Epilepsie, Angina pectoris, kongestive Herzinsuffizienz, Arrhythmie, schwere Hypersensitivitätsreaktionen, Hautläsionen an Injektionsstelle, schwere Nieren-/Leberinsuffizienz, schwerwiegende Leberfunktionsstörungen, Nephrotisches Syndrom, akute Myeloidsuppression, Alkoholmissbrauch, Regelmässige Kontrolle der Leberenzyme, grosses resp. Differentialblutbild, ggf. Schilddrüsenfunktionsst. **IA:** Medikamente mit enger therapeutischer Breite und/oder Metabolisierung über CYP P450 wie Antiepileptika oder Antidepressiva. Häufigste UAW: Grippeähnliche Symptome, Entzündungen, Hautreaktionen und Schmerzen an der Injektionsstelle, Kopfschmerzen, Myalgie, Arthralgie, Müdigkeit, Rigor, Fieber, Anstieg der Leberfunktionswerte, Pruritus, Ausschläge, Urinkariz, Alopezie, Neutropenie, Lymphopenie, Leukopenie, Thrombozytopenie, Anämie, Durchfall, Erbrechen, Übelkeit, Depression, Schlaflosigkeit, Dyspnoe. **P:** Rebif® 8,8 µg/0,2 ml und 22 µg/0,5 ml Fertigspritzen: 6+6 (Stampackung)\*, 22 µg/0,5 ml oder 4,4 µg/0,5 ml Fertigspritzen: je 12\*. Rebif® multidose™ Patronen zu 66 µg/1,5 ml oder 132 µg/1,5 ml: je 4\*. Rebif® RebiDose™ 8,8 µg/0,2 ml und 22 µg/0,5 ml Fertiggpens: 6+6 (Startpackung)\*, 22 µg/0,5 ml oder 4,4 µg/0,5 ml Fertiggpens: je 12\*. [B] (\*=kassenzulässig). Für detaillierte Informationen siehe [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch); JAN16

1. Swissmedic (<https://www.swissmedic.ch/swissmedic/de/home/services/zugelassene-preparate/human-und-tierarzneimittel.html> [Stand: 10.09.2018])



Merck (Schweiz) AG Chamerstrasse 174 CH-6301 Zug [www.merck.ch](http://www.merck.ch)

ERFAHRUNG, DIE ZÄHLT.

**Rebif®**  
(Interferon beta-1a)

# GENERAL INFORMATION

<b>Date</b>	October 23-25, 2019
<b>Venue</b>	SwissTech Convention Center Route Louis-Favre 2, 1024 Ecublens, CH www.stcc.ch
<b>Website</b>	sfcns2019.congress-imk.ch
<b>Scientific committee</b>	Prof. Karl-Olof Lövblad, MD, Geneva, Congress President Bigna Bölsterli, MD, Zurich Prof. Kim Do Cuénod, MD, Lausanne PD Barbara Goeggel Simonetti, MD, Bern/Bellinzona Harald F. Grossmann, Basel Prof. Doron Merkler, MD, Geneva Prof. Krassen Nedeltchev, MD, Aarau Prof. Andreas Raabe, MD, Bern Prof. Kai Rösler, MD, Bern und Basel Prof. Andrea Rossetti, MD, Lausanne Prof. Christoph Stippich, MD, Zurich Prof. Barbara Tettenborn, MD, St.Gallen Prof. Dimitri Van De Ville, PhD, Lausanne Prof. Sebastian Walther, MD, Bern Rebekka Zimmermann, MD, Bern

## Participating professional associations

Swiss Association for Neurophysiological Diagnostic SFND/ASDN  
Association of neurosurgical nursing staff Switzerland IG-NOPPS  
with a separate one-day program on October 24, 2019.

Registration fee	Early Bird until 15.09.2019		Regular from 16.09.2019	
	1 day	3 days	1 day	3 days
Member physicians	150.-	300.-	200.-	350.-
Non-member physicians	200.-	400.-	250.-	450.-
Member residents, SAYN   SYNS   YouClin	60.-	120.-	80.-	160.-
Non-member residents	70.-	140.-	90.-	180.-
Students, MTM, PhD	50.-	100.-	70.-	140.-
SFND   IG-NOPPS*	50.-		80.-	

\* The registration fees IG-NOPPS for the congress are covered by the SSNS.  
Therefore the participation is free of charge.

Fees in CHF

## Registration

Online via [www.sfcns2019.congress-imk.ch](http://www.sfcns2019.congress-imk.ch) for your participation at the congress, your accommodation in Lausanne and the Networking Event at the Olympic Museum, Lausanne.

## Cancellation policy

**IMK** must be informed about cancellations in writing. Until 31.08.2019, 50% of the costs will be reimbursed. After 31.08.2019, no refunds will made.

## Abstract Submission

via congress website until **05.05.2019**

## Credits

Credits will be requested from various societies.

## Professional Congress Organizer (PCO)

**IMK** Institute for medicine and communication Ltd  
Münsterberg 1, CH-4001 Basel  
Phone: +41 61 271 35 51 | Fax: +41 61 271 33 38  
congress@imk.ch | www.imk.ch

The Swiss Federation of Clinical Neuro-Societies (SFCNS) was officially founded in 2009. First steps in that direction were taken at the Joint Meeting of six Clinical Neuroscience Societies in April 2008 in Montreux, which commemorated the centenary of the Swiss Neurological Society.

Following this great success and overwhelming approval, the Swiss Neurological Society (SNS), Swiss Society of Neurosurgery (SSNS), Swiss Society of Clinical Neurophysiology (SSNC), Swiss Society of Neuropaediatrics (SSNP), Swiss Society of Neuroradiology (SSNR), and Swiss Society of Neuropathology (SSNPath) decided to close ranks and form a Swiss Federation of Clinical Neuro-Societies (SFCNS) which marked the beginning of a new cooperative effort to strengthen the clinical neurosciences in Switzerland. The federation should formalise and structure the joint medico-political, educational and clinical research efforts.

Its further aim is to hold common meetings on a regular basis to facilitate mutual interactions and be open also to other medical groups pursuing clinical neuroscience interests. It will also be a cooperative partner of the Swiss Society for Neuroscience.

### Ordinary members SFCNS

Swiss Neurological Society SNS | [www.swissneuro.ch](http://www.swissneuro.ch)  
Swiss Society of Neurosurgery SSNS | [www.swissneurosurgery.ch](http://www.swissneurosurgery.ch)  
Swiss Society of Clinical Neurophysiology | [www.sgkn.ch](http://www.sgkn.ch)  
Swiss Society of Neuropaediatrics SSNP | [www.neuropaediatricie.ch](http://www.neuropaediatricie.ch)  
Swiss Society of Neuroradiology SSNR | [www.swissneuroradiology.ch](http://www.swissneuroradiology.ch)  
Swiss Society of Neuropathology SSNPath | [www.ssn.uzh.ch](http://www.ssn.uzh.ch)  
Swiss Society of Biological Psychiatry SSBP | [www.ssbp.ch](http://www.ssbp.ch)

### Associated members

Swiss Headache Society SHS | [www.headache.ch](http://www.headache.ch)  
Swiss Society for Neurorehabilitation SSNRehab | [www.sgnr.ch](http://www.sgnr.ch)  
Swiss Association of Neuropsychology | [www.neuropsychy.ch](http://www.neuropsychy.ch)  
Swiss Society of Behavioural Neurology SSBN | [www.sgvn.ch](http://www.sgvn.ch)  
Swiss Stroke Society SSS | [www.neurovasc.ch](http://www.neurovasc.ch)

### Extraordinary members

Swiss League Against Epilepsy SLaE | [www.epi.ch](http://www.epi.ch)  
aphasie suisse | [www.aphasie.ch](http://www.aphasie.ch)

### SFCNS Executive Board

<b>President</b>	Prof. Karl Schaller, MD
<b>Vice president</b>	Prof. Philippe Lyrer, MD
<b>Past President</b>	Prof. Anton Valavanis, MD
<b>Secretary   Treasurer</b>	Prof. Barbara Tettenborn, MD
<b>Assessor SSNR</b>	Prof. Jan Gralla, MD
<b>Assessor SSNC</b>	Prof. Andreas Raabe, MD
<b>Assessor SSNP</b>	Prof. Christian Korff, MD
<b>Assessor SSBP</b>	Prof. Martin Hatzinger, MD
<b>Assessor SSCN</b>	Prof. Kai Rösler, MD
<b>General Secretary</b>	Harald F. Grossmann

---

### Diamond Partners 2019

We thank the Diamond Partner Companies for their support.